Omalizumab Treatment in Chronic Inducible Urticaria: A Systematic Review of Published Evidence

Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in chronic inducible urticarias (CIndUs), which are frequently H1-antihistamine resistant.

http://ift.tt/2gXpKyT